Form 4: Verona Pharma CFO Sells 400,000 Shares Under Pre-Arranged Trading Plan

Verona Pharma plc's Chief Financial Officer, Mark W. Hahn, sold 400,000 ordinary shares on June 11, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Mark W. Hahn, Chief Financial Officer of Verona Pharma plc (VRNA), disposed of 400,000 Ordinary Shares.
• The transaction occurred on June 11, 2025.
• The shares were sold at a weighted average price of $11.4009 per Ordinary Share.
• The sale was executed pursuant to a Rule 10b5-1 plan, which was adopted on January 29, 2025.
• The selling price ranged from $11.375 to $11.4575 per Ordinary Share, or $91.00 to $91.66 per American Depositary Share (ADS).
• Following this transaction, Mr. Hahn beneficially owns 12,278,992 Ordinary Shares.
• These remaining shares include 2,450,000 Ordinary Shares underlying Restricted Share Units and 9,828,992 Ordinary Shares underlying ADSs.
• Each American Depositary Share (ADS) represents eight (8) Ordinary Shares of Verona Pharma plc.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale could be perceived negatively, the fact that it was conducted under a pre-arranged 10b5-1 plan mitigates concerns that it's based on new, negative information. It's a routine disclosure for a planned transaction.

Negatives

• The sale of 400,000 shares by a Chief Financial Officer, while part of a pre-arranged plan, represents a reduction in insider ownership, which some investors may view as a negative signal.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. It reflects a routine disclosure of a pre-planned stock sale by a corporate executive.

Stakeholder Impact

• Shareholders: The sale by a key executive could be interpreted differently by shareholders; some may view it as a normal part of executive compensation and financial planning, while others might see it as a slight negative signal regarding future prospects, despite the 10b5-1 plan.

Key Dates

Keywords

Verona Pharma, VRNA, SEC Form 4, Insider Trading, Share Sale, Mark W. Hahn, Chief Financial Officer, Rule 10b5-1 Plan, Ordinary Shares, American Depositary Shares, Executive Compensation